1. Introduction

The development of effective therapy for children with acute lymphoblastic leukemia (ALL) is one of the greatest successes of clinical oncology, with long-term survival achieved in about 90% of children 1-10 years of age (Pui et al. 2008, Pulte et al. 2008). However, cure rates for adults with ALL remain relatively low, at only 40%-50% (Gokbuget et al. 2009, Larson et al. 2008). In the last two decades significant improvements in survival for older adolescent and adults (aged 15-59 years) with ALL have been observed, being especially evident in patients aged 15-19 yr.

Age is a continuous prognostic variable in ALL with no single age at which prognosis deteriorates markedly. Within childhood ALL populations, older children have shown inferior outcomes (Pulte et al. 2009, Smith et al. 2010) while younger adults have shown superior outcomes among adult ALL patients (Moorman et al. 2010, Juliusson et al. 2010). The definition of the age range that encompasses the adolescent and young adults (AYA) patient is controversial, ranging from 15 to 21 yr in some studies, from 15-30 yr in others or even from 15 to 40-45 yr in others. This chapter will focus on the results of treatment of AYA with ALL.

2. Clinical and biologic characteristics in adolescents and young adults

The incidence of ALL decreases with age, ranging from 9-10 cases/100,000 persons/year in childhood (representing 30% of all cancers) to 1-2 cases/100,000 persons/year in adults. In adolescents the incidence is 3 cases/100,000 persons/year and represents 6% of all cancers at that age (Bleyer et al. 2006).

Several clinical and biologic characteristics of ALL are age-dependent. In this sense, T-ALL is more frequent in AYA (25%) than in children (10-15%) or in older adults (Pullen et al. 1999). However, the most important differences lie in cytogenetic and molecular characteristics. For example, there is a lower frequency of hyperdiploidy >50 chromosomes or ETV6/RUNXI (previously TEL/AML1) in AYAs (20%) compared to children 1 to 9 years of age (>30%) (Moorman et al. 2010). In addition, the frequency of MLL (myeloid-lymphoid leukemia or mixed lineage leukemia gene, usually associated with 11q23) rearrangements in
non-infant ALL increases with age, being infrequent in children 1-9 yr of age and about 6% in adults (Moorman et al 2010). Regarding structural changes, there is a progressive increase in the frequency of t(9;22)(q34;q11) or \textit{BCR-ABL} rearrangements, ranging from less than 3% in children under 18 yr. to 6% at ages 18-25 and to 15-20% at ages 25-35 yr, and to more than 30% over the age of 35 yr (Secker-Walker et al 1991). Finally, in recent studies, adolescents were more likely to have detectable minimal residual disease (MRD) during or at the end of remission induction (Pui et al 2011).

In summary, with increasing age there is a progressive increase in the frequency of subsets of ALL patients with genetic abnormalities associated with poor prognosis and these changes have already become evident in AYA patients.

As far as host factors are concerned, several features are observed in less young patients, being responsible for increased treatment toxicity. They include differences in the metabolism of chemotherapeutic agents, depleted marrow reserve and increased extramedullary toxicity. All these issues increase the frequency of life-threatening infections, organ failure, and treatment delays and dose reductions in planned chemotherapy.

3. Which is the best treatment strategy? Pediatric-based vs. adult-based treatments

3.1 Retrospective comparative studies

A number of comparisons of the clinical outcome of adolescents enrolled in adult and pediatric clinical trials have resulted in interesting observations about the appropriate treatment strategy for prospective studies in AYA. Several retrospective reports have shown that adolescents (15-20 yr.) and young adults treated by adult oncologists or hematologists with adult ALL protocols have poorer outcomes than similarly aged patients treated by pediatricians with pediatric protocols, despite having similar biologic characteristics of the disease (Boissel et al 2003, de Bont et al 2004, Testi et al 2004, Hallbook et al 2006, Schroeder et al 2006, Ramanujachar et al 2007, Lopez-Hernandez et al 2008, Stock et al 2008, Al-Khabori et al 2010).

The first study in which such different outcomes were reported was performed in France (Boissel et al 2003). A comparison of AYA aged 15-20 yr. treated with the pediatric-based protocol FRALLE-93 (n=77) with patients of the same age and comparable clinical and biologic characteristics of ALL who received the adult-based protocol LALA-94 (n=100) showed a complete remission (CR) rate of 94% vs. 83%. After a median follow-up of 3.5 yr, the event-free survival (EFS) probabilities were 67% vs. 41% at 5 years. Multivariate analysis showed an independent influence of the protocol on the outcome. The differences in the drugs employed and, especially in the dose-intensity, could explain the better results of the FRALLE-93 protocol. In this protocol the cumulated dose of prednisone was five-fold higher, the vinca alkaloids three-fold and the asparaginase 20-fold higher than in the LALA-94 study. In addition, in the FRALLE-93 study the dose of prednisone in induction was higher and asparaginase was also given in this period, in contrast with the LALA-94 trial. Moreover, the time interval between CR and post-remission therapy was 2 days in FRALLE-93 vs. 7 days in the LALA-94 study.

The North-American Cancer and Acute Leukemia Group B (CALGB) and the Children’s Cancer Group (CCG) performed a retrospective comparison of presenting features, planned treatment, CR rate, and outcome of 321 AYA aged 16 to 20 years who were treated on consecutive trials in either the CCG or the CALGB from 1988 to 2001 (Stock et al 2008). Both
coHORTS WERE COMPARABLE FOR THE MAIN CLINICAL AND BILOGIC CHARACTERISTICS, ALTHOUGH THE MEDIAN AGE OF THE PATIENTS IN THE CALGB STUDIES WAS 19 YR. COMPARED TO 16 YR. FOR THE CCG PATIENTS. CR RATES WERE IDENTICAL (90%) FOR BOTH THE CALGB AND CCG AYA. THE CCG AYA HAD A 63% EFS AND 67% OVERALL SURVIVAL (OS) PROBABILITIES AT 7 YEARS IN CONTRAST TO THE CALGB AYA, IN WHOM THE 7-YEAR EFS WAS ONLY 34% AND THE OS WAS 46%. WHILE THE CALGB AYA AGED 16 TO 17 YEARS ACHIEVED SIMILAR OUTCOMES TO ALL THE CCG AYA WITH A 7-YEAR EFS OF 55%, THE EFS FOR 18- TO 20-YEAR-OLD CALGB PATIENTS WAS ONLY 29%. CALGB AYAs HAD A SIGNIFICANT INCREASE IN CNS RELAPSE (11%) COMPARED TO CCG AYAs (1.5%). COMPARISON OF THE REGIMENS SHOWED THAT THE CCG AYA RECEIVED EARLIER AND MORE INTENSIVE AND PROLONGED CNS PROPHYLAXIS AND HIGHER CUMULATIVE DOSES OF NONMYELOSUPPRESSIVE AGENTS (VINCA ALKALOID, STEROIDS AND ASPARAGINASE), AS WELL AS LONGER DURATION OF MAINTENANCE THERAPY THAN CALGB AYAs. THERE WERE NO DIFFERENCES IN OUTCOMES IN THOSE WHO REACHED MAINTENANCE THERAPY ON TIME COMPARED WITH THOSE WHO WERE DELAYED.


ONLY ONE POPULATION-BASED STUDY FROM FINLAND SHOWED THAT THE OUTCOME OF AYA WITH ALL TREATED WITH PEDIATRIC OR ADULT PROTOCOLS WAS COMPARABLE (UVASALO ET AL 2008). ONE HUNDRED AND TWENTY-EIGHT PATIENTS (10-16 YR, MEDIAN AGE 12.9 YR) WERE TREATED WITH THE PEDIATRIC NORDIC (NOPHO) PROTOCOLS AND 97 PATIENTS (17-25 YR, MEDIAN AGE 18.9 YR) WITH FINNISH LEUKEMIA GROUP NATIONAL PROTOCOLS. ALL PATIENTS WERE CENTRARLY REFERRED AND TREATED IN FIVE ACADeMIC CENTERS. THE 5-YEAR EFS WAS 67% FOR THE PEDIATRIC TREATMENT GROUP AND 60% FOR THE ADULT TREATMENT GROUP. THERE WERE NO SIGNIFICANT DIFFERENCES IN THE CUMULATIVE DOSES OF CORTICOSTEROIDS, VINCristINE AND ASPARAGINASE BETWEEN PEDIATRIC AND ADULT PROTOCOLS, ALTHOUGH PEDIATRIC PROTOCOLS USED A HIGHER CUMULATIVE DOSE OF METHOTREXATE AND LOWER
Table 1. Retrospective comparative studies in adolescents and young adults with acute lymphoblastic leukemia treated with pediatric-based (P) vs. adult-based (A) protocols.

<table>
<thead>
<tr>
<th>Country (reference)</th>
<th>Protocol</th>
<th>Age (yr)</th>
<th>N</th>
<th>CR (%)</th>
<th>EFS (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>USA (32)</td>
<td>CCG(P)</td>
<td>16-20</td>
<td>197</td>
<td>90</td>
<td>63</td>
</tr>
<tr>
<td></td>
<td>CALGB(A)</td>
<td></td>
<td>124</td>
<td>90</td>
<td>34</td>
</tr>
<tr>
<td>France (12)</td>
<td>FRALLE93(P)</td>
<td>15-20</td>
<td>77</td>
<td>94</td>
<td>67</td>
</tr>
<tr>
<td></td>
<td>LALA94 (A)</td>
<td></td>
<td>100</td>
<td>83</td>
<td>41</td>
</tr>
<tr>
<td>Holland (13)</td>
<td>DCOG (P)</td>
<td>15-18</td>
<td>47</td>
<td>98</td>
<td>69</td>
</tr>
<tr>
<td></td>
<td>HOVON (A)</td>
<td></td>
<td>44</td>
<td>91</td>
<td>34</td>
</tr>
<tr>
<td>Italy (35)</td>
<td>AIEOP (P)</td>
<td>14-18</td>
<td>150</td>
<td>94</td>
<td>80</td>
</tr>
<tr>
<td></td>
<td>GIMEMA (A)</td>
<td></td>
<td>95</td>
<td>89</td>
<td>71</td>
</tr>
<tr>
<td>Sweden (11)</td>
<td>NOPHO-92(P)</td>
<td>10-40</td>
<td>144</td>
<td>99</td>
<td>65</td>
</tr>
<tr>
<td></td>
<td>Adult (A)</td>
<td></td>
<td>99</td>
<td>90</td>
<td>48</td>
</tr>
<tr>
<td>UK (25)</td>
<td>ALL97 (P)</td>
<td>15-17</td>
<td>61</td>
<td>98</td>
<td>65</td>
</tr>
<tr>
<td></td>
<td>UKALLXII(A)</td>
<td></td>
<td>67</td>
<td>94</td>
<td>49</td>
</tr>
<tr>
<td>Canada (1)</td>
<td>DFCI (P)</td>
<td>17-64</td>
<td>32</td>
<td>84</td>
<td>83*</td>
</tr>
<tr>
<td></td>
<td>Adult (A)</td>
<td>17-69</td>
<td></td>
<td>40</td>
<td>93</td>
</tr>
<tr>
<td>Mexico (16)</td>
<td>LALIN (P)</td>
<td>15-25</td>
<td>20</td>
<td>90</td>
<td>70</td>
</tr>
<tr>
<td></td>
<td>LALA (A)</td>
<td></td>
<td>20</td>
<td>80</td>
<td>40</td>
</tr>
<tr>
<td>Finland (38)</td>
<td>NOPHO (P)</td>
<td>10-25</td>
<td>128</td>
<td>96</td>
<td>67</td>
</tr>
<tr>
<td></td>
<td>ALL (A)</td>
<td></td>
<td>97</td>
<td>97</td>
<td>60</td>
</tr>
</tbody>
</table>

N: number of patients; CR: complete remission. EFS: event-free survival.
* Overall survival

In summary, the 5- to 6-yr EFS rate for AYA treated with pediatric regimens ranges from 65% to 70% vs. 35% to 50% for adult regimens in almost but not all retrospective comparative studies. However, it is of note that these studies have mainly focused on patients aged 15-21 years, but few have evaluated the results in young adults up to 30 years or more, in whom the frequency of adverse prognostic factors is progressively increasing.

The reasons for the better results of pediatric protocols are multiple (Stock 2010). The first and probably the most important reason lay in the protocol itself. The dose-intensity and the dose-density of the key chemotherapeutic agents for ALL are clearly higher in pediatric protocols. This is especially relevant for drugs such as vincristine (usually capped to 2 mg in adult protocols), glucocorticoids, asparaginase and methotrexate. Conversely, pediatric-
based protocols include lower doses of alkylating agents, high-dose cytarabine and antracyclines than adult trials. In addition CNS prophylaxis is more intense and prolonged in pediatric regimens than in adult trials. Most of the pediatric protocols include delayed intensifications and an extended maintenance chemotherapy phase, the former being omitted in many adult trials. The use of allogeneic stem cell transplantation (SCT) as part of first line therapy (associated with a transplant-related mortality [TRM] of 20%), is restricted to patients with very high-risk features in pediatric trials, whereas it is more widely used in adult trials, even in standard-risk patients in first CR.

The second reason is the tolerability to essential drugs such as asparaginase, steroids and vincristine, which is poorer in AYA compared to children, being a reflection of changes in the metabolism of these drugs during late adolescence. The incidences of diabetes mellitus, pancreatitis, thrombosis and osteonecrosis are more frequent in the former group. The increased toxicity influences adherence to treatment, which is critical for the outcome of ALL patients.

The third reason is the disparity in the practice patterns of the pediatric and adult hematologists/oncologists and patient compliance. Adherence to treatment is usually higher in pediatric than in adult-derived studies, probably due both to a highly skilled supportive staff, the better tolerability of pediatric protocols and a stricter control of time points of chemotherapy delivery in pediatric than in adult hematology units (Burke et al 2007) However, in the U.S. and Canada most children and adolescents with ALL treated with pediatric protocols are managed in institutions and academic centers participating in national-sponsored clinical trials, whilst most AYA treated with adult protocols are managed throughout study groups by community-based medical oncologists. The fact that the most striking differences are observed in the 18 to 20-years-old group could be explained by the emancipation of some of these patients from parental control and support and the possible need to face significantly more challenges in access to health care due to insurance issues (Kantarjian et al 2009).

3.2 Prospective trials
3.2.1 Results of the treatment of adolescents in pediatric trials
Barry et al reported the outcome of adolescents treated in the Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocols conducted between 1991 and 2000 (Barry et al 2007). A total of 844 patients aged 1 to 18 years, with newly diagnosed ALL were enrolled into two consecutive DFCI-ALL Consortium Protocols. Outcomes were compared in three age groups: children aged 1 to 10 years (n = 685), young adolescents aged 10 to 15 years (n = 108), and older adolescents aged 15 to 18 years (n = 51). With a median follow-up of 6.5 years, the 5-year EFS for those aged 1 to 10 years was 85%, compared with 77% for those aged 10 to 15 years, and 78% for those aged 15 to 18 years. There was no difference in the rate of treatment-related complications between the 10- to 15-year and 15- to 18-year age groups.

Nachman et al reported the results of the CCG1961 trial including AYA up to 21 yr (Nachman et al 2009). The EFS and overall survival (OS) rates were 71.5% and 77.5%, respectively. Rapid responder patients randomly assigned to augmented therapy had 5-year EFS 81.8% vs 66.8% for patients receiving standard therapy, but 1 versus 2 interim maintenance and delayed intensification courses had no significant impact on EFS. WBC count over 50x10^9/L was an adverse prognostic factor. Given the excellent outcome with this chemotherapy there seems to be no role for the routine use of stem cell transplantation in first remission.
In turn, the results of the total therapy studies XIIIA, XIIIB, XIV and XV from St Jude Children’s Research Hospital including 963 pediatric patients, 89 of whom were older adolescents (aged 15 to 18 yr.), have recently been published (Pui et al 2011). In the first three studies the 44 older adolescents had significantly poorer EFS and OS than the 403 younger patients. On the contrary, in study XV (incorporating the level of MRD to guide treatment, with featured intensive methotrexate, vincristine, glucocorticoid and asparaginase and early triple intrathecal chemotherapy for higher risk ALL) the EFS of 45 older adolescents was 86.4%, similar to 87.4% for the 453 younger children. The OS was also comparable (87.9% vs. 94.1%, respectively). The authors concluded that most older adolescents with ALL can be cured with risk-adjusted intensive chemotherapy without SCT.

In summary, with modern approaches of treatment of ALL with pediatric-based protocols the unfavorable prognosis of adolescents is disappearing and hopefully, this improvement could be translated to young adults.

3.2.2 Results of prospective studies in adolescent and young adults

Some studies have evaluated or are currently evaluating the feasibility and results of the pediatric-based protocols administered to adults up to 30 or even up to 50 or 60 years of age (table 2). The Spanish PETHEMA group compared the results of the pediatric protocol ALL96 in adolescents (15-18yr, n=35) and young adults (18-30 yr, n=46) with standard-risk (SR) ALL (Ribera et al 2008). Both groups were comparable for the main clinical and biologic characteristics of ALL. The CR rate was 98% and after a median follow-up of 4.2 yr., 6-year EFS and OS were 61% and 69%, with no differences between adolescents and young adults. No significant differences were observed in the timing of treatment delivery, although the hematologic toxicity in consolidation and reinforcement cycles was higher in young adults than in adolescents. These results suggest that pediatric protocols can be effectively and safely employed in adult patients with SR ALL, at least up to the age of 30 yr.

<table>
<thead>
<tr>
<th>Country (reference)</th>
<th>Protocol</th>
<th>Age (yr)</th>
<th>N</th>
<th>CR (%)</th>
<th>EFS (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spain (26)</td>
<td>PETHEMA ALL-96</td>
<td>15-18</td>
<td>35</td>
<td>94</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td></td>
<td>19-30</td>
<td>46</td>
<td>100</td>
<td>63</td>
</tr>
<tr>
<td>France (32)</td>
<td>GRAALL-2003</td>
<td>15-45</td>
<td>172</td>
<td>95</td>
<td>58</td>
</tr>
<tr>
<td>USA (6)</td>
<td>DFCI</td>
<td>18-50</td>
<td>74</td>
<td>82</td>
<td>72.5**</td>
</tr>
<tr>
<td>Canada (34)</td>
<td>Modified DFCI</td>
<td>17-71</td>
<td>68</td>
<td>85</td>
<td>65***</td>
</tr>
<tr>
<td>France (10)</td>
<td>FRALLE2000</td>
<td>18-55</td>
<td>40</td>
<td>90</td>
<td>72***</td>
</tr>
</tbody>
</table>

* Results restricted to adolescents; **Estimated at 2 years; *** Overall survival.

N: number of patients; CR: complete remission. EFS: event-free survival.

Table 2. Prospective studies in adolescents and young adults with acute lymphoblastic leukemia treated with pediatric-based or inspired protocols
The French GRAALL group has reported the results of the pediatric-inspired GRAALL-2003 study including 215 patients aged 15-60 yr (Huguet et al 2009). In this study there was an 8.6-fold, 3.7-fold and 16-fold increase in cumulative doses of prednisone, vincristine and asparaginase, respectively, compared with the previous adult-based LALA-94 protocol, although the GRAALL-2003 trial retained some adult options, such as allogeneic SCT for patients with high-risk ALL. The CR rate was 93.5% and at 42 months the EFS and overall survival (OS) rates were 55% and 60%, respectively. The CR rate, EFS and OS compared favorably with the previous LALA-94 experience. It is of note, however, that in patients over 45 yr there was a higher cumulative incidence of chemotherapy-related deaths (23% vs. 5%) and deaths in first CR (22% vs. 5%), although the incidence of relapse remained stable (30 vs. 32%). The results of this study suggest that pediatric-inspired therapy is feasible in young adults with ALL at least until the age of 45 yr, in whom the outcome clearly improves.

Based on the promising results obtained in adolescents with ALL, the DFCI Combined Adult/Pediatric ALL Consortium has applied a true pediatric protocol to adults aged 18-50 yr (DeAngelo et al 2006). Specifically, the investigators used an extended course of asparaginase for 30 weeks. The preliminary results in 94 patients, with a median age of 28 yr have shown a CR in 79 patients (84%). With a median follow-up of 45 months, the estimated DFS rate was 66% and the OS rate was 68%. This study proved that extended asparaginase treatment was feasible in adults and the drug-related toxicity was manageable, although the incidence of pancreatitis (13%) and thrombosis/embolism (19%) was a matter of concern. In turn, the Princess Margaret Hospital used a modified Dana Farber Cancer Institute pediatric protocol in 68 adult patients (17 to 71 yr), with a CR rate of 85% and 3-yr OS and DFS of 65% and 77%, respectively (Storring et al 2009). The University of South California group (Srivastava et al 2008) used an augmented BFM pediatric regimen with eight doses of pegylated asparaginase to treat adults with ALL aged 19-57 yr (median 33), with a 3-yr projected EFS of 65%. Toxicity attributable to asparaginase was frequent but manageable. However, older patients had significantly less tolerance to asparaginase, vincristine and steroids compared to children or adolescents. In the FRALLE group from France 28 Philadelphia chromosome-negative adult ALL patients 16 to 57 years of age were treated in the FRALLE 2000 protocol consisting of a prednisone pre-phase and a four-drug induction including asparaginase, consolidation, delayed intensification and maintenance chemotherapy. The 4-yr DFS was 90% vs. 47% seen in matched historical controls (Haiat et al 2011).

The largest prospective phase II trial to evaluate the feasibility of the use of a true pediatric regimen in AYA is currently ongoing in the US (C-10403 trial) (available at www.clinicaltrials.gov. NCT00558519) AYAs from 16 to 39 yr are treated by adult oncologists/hematologists with one treatment arm of the current AALL0232 trial from the pediatric COG group. More than half of the 300 planned patients have been currently enrolled. This study will prospectively analyze the genetic characteristics, MRD, treatment adherence, tolerability and psycho-social and socio-economic conditions that likely influence treatment outcomes.

The results from these prospective studies demonstrate the feasibility and tolerability of pediatric-based regimens in AYA with SR ALL, at least until 30-50 yr. All these trials have the increased cumulative dosages of the most important drugs for ALL therapy, the cautious observance of dose-intensity and the reduction of the delays between the different phases of the therapy in common. If these results can be confirmed with a longer follow-up, they will
have an impact on the clinical management of AYA patients in the future. Finally, few specific data are available on long-term complications of successful treatment of AYA (see www.survivorshipguidelines.org by the COG group) and a comprehensive approach to the follow-up for this significant group of patients with ALL is lacking. The next generation of studies, incorporating biological, pharmacological and psychosocial issues will further improve the cure rate and quality of life of these patients.

4. Acknowledgment

Supported in part by grants RD06/0020/1056 from RTICC, Instituto Carlos III, PI051490 from Fondo de Investigaciones Sanitarias and FIJC P/EF-10 from Jose Carreras Leukemia Foundation.

5. References


[37] Available at www.clinicaltrials.gov NCT00558519.
This book provides a comprehensive overview of the basic mechanisms underlying areas of acute leukemia, current advances, and future directions in management of this disease. The first section discusses the classification of acute leukemia, taking into account diagnoses dependent on techniques that are essential, and thankfully readily available, in the laboratory. The second section concerns recent advances in molecular biology, markers, receptors, and signaling molecules responsible for disease progression, diagnostics based on biochips and other molecular genetic analysis. These advances provide clinicians with important understanding and improved decision making towards the most suitable therapy for acute leukemia. Biochemical, structural, and genetic studies may bring a new era of epigenetic based drugs along with additional molecular targets that will form the basis for novel treatment strategies. Later in the book, pediatric acute leukemia is covered, emphasizing that children are not small adults when it comes to drug development. The last section is a collection of chapters about treatment, as chemotherapy-induced toxicity is still a significant clinical concern. The present challenge lies in reducing the frequency and seriousness of adverse effects while maintaining efficacy and avoiding over-treatment of patients.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
